ATR and leukemia: To determine whether SRSF2 mutations are sufficient to sensitize leukemia cells to inhibition of ATR, CHK1, and WEE1, we tested the sensitivity of ten isogenic SRSF2 mutant and four wild-type K562 clones to inhibitors of these kinases.